Malgorzata K. Tuxen - Publications

Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?

Journal: British journal of cancer

Published: November 02, 2025

Metastatic triple-negative breast cancer - current treatment strategies in the Nordics: a modified Delphi study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 15, 2024

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 23, 2024

Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: October 19, 2023

Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 15, 2023

Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial.

Journal: Scientific reports

Published: August 09, 2019

Heavy-load resistance exercise during chemotherapy in physically inactive breast cancer survivors at risk for lymphedema: a randomized trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: July 30, 2019

Are previous episodes of bacterial vaginosis a predictor for vaginal symptoms in breast cancer patients treated with aromatase inhibitors?

Journal: Post reproductive health

Published: February 08, 2018

Is DBCG abreast of new developments?

Journal: Acta oncologica (Stockholm, Sweden)

Published: January 04, 2018

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 10, 2017

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 30, 2017

Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.

Journal: Future science OA

Published: February 08, 2017